RxDoctor Payments Data

Mary Carroll, MD

Endocrinology, Diabetes & Metabolism · Bend, ORNPI 1821004599

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,045 of the $32,088 with a category attached, or 90.5%. Novo Nordisk accounts for 97.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $11,921 and has fallen 99.0% since, to $125 in 2025.

$32,088in general payments, 2019–2025

Across 69 payments — averaging $465.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$31K
  • Amgen$238
  • AstraZeneca$119
  • Tandem Diabetes Care, Inc.$61
  • Medtronic$50
  • Dexcom, Inc.$44
  • plus $185 from 10 others

What the payments were for

  • Consulting fees$2,0406%
  • Speaking & faculty fees$29,04591%
  • Food & beverage$9133%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,088 in reported general payments places this provider in the 80th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.

See all endocrinology, diabetes & metabolism providers in Oregon

Medicare billing

Part B allowed, 2024
$267,417
Medicare patients
2,099
Services billed
5,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide264$440,371
JardianceEmpagliflozin328$408,552
OzempicSemaglutide166$240,935
MounjaroTirzepatide76$119,023
Tresiba Flextouch U-200Insulin Degludec25$32,643
FarxigaDapagliflozin Propanediol23$29,353
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$22,064
JanuviaSitagliptin Phosphate15$15,359
Tresiba Flextouch U-100Insulin Degludec23$13,993
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$13,939
Lantus SolostarInsulin Glargine,hum.Rec.Anlog108$13,673
SynthroidLevothyroxine Sodium196$11,144
RybelsusSemaglutide12$11,069
Levothyroxine Sodium992$10,276
Cabergoline23$7,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$17$559,393340 claims
Boehringer IngelheimJardiance$27$408,552328 claims
Novo NordiskOzempic, Rybelsus$31,391$252,003178 claims
AstraZenecaFarxiga$119$29,35323 claims
MerckJanuvia$17$15,35915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.

Other endocrinology, diabetes & metabolism in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →